Search Results

IO Biotech today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial.

IO Biotech announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 4-6, 2024 in New York.

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.

IO Biotech today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the first quarter ended March 31, 2024.

IO Biotech (Nasdaq: IOBT) today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024.